Figure 6.
Figure 6. sPLA2 treatment of DCs enhances their stimulatory capacity in the allogeneic MLR: cytokine responses. Day-5 DCs were treated in the presence of FCS or LPD-FCS for 48 hours with sPLA2 alone (10 μg/mL) or in combination with TNF-α (100 U/mL) plus IL-1β (1 ng/mL). Cells were washed and used as stimulators of 3 different preparations of allogeneic PBMCs depleted of CD14+ cells. Triplicate supernatants were harvested and pooled at 24 and 96 hours. Cytokine profiles were determined using a commercial cytokine bead array and a flow cytometer (both from BD Biosciences). The 24-hour values are shown. LPD indicates lipoprotein-deficient.

sPLA2 treatment of DCs enhances their stimulatory capacity in the allogeneic MLR: cytokine responses. Day-5 DCs were treated in the presence of FCS or LPD-FCS for 48 hours with sPLA2 alone (10 μg/mL) or in combination with TNF-α (100 U/mL) plus IL-1β (1 ng/mL). Cells were washed and used as stimulators of 3 different preparations of allogeneic PBMCs depleted of CD14+ cells. Triplicate supernatants were harvested and pooled at 24 and 96 hours. Cytokine profiles were determined using a commercial cytokine bead array and a flow cytometer (both from BD Biosciences). The 24-hour values are shown. LPD indicates lipoprotein-deficient.

Close Modal

or Create an Account

Close Modal
Close Modal